Regeneron’s trial fails to reach statistical significance for primary endpoint

​Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab and cemiplimab for metastatic melanoma failed to reach statistical significance for the primary endpoint.

The post Regeneron’s trial fails to reach statistical significance for primary endpoint appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.